Literature DB >> 12072516

Herpes simplex virus type 1/adeno-associated virus hybrid vectors mediate site-specific integration at the adeno-associated virus preintegration site, AAVS1, on human chromosome 19.

Thomas Heister1, Irma Heid, Mathias Ackermann, Cornel Fraefel.   

Abstract

Herpes simplex virus type 1 (HSV-1)-based amplicon vectors have a large transgene capacity and can efficiently infect many different cell types. One disadvantage of HSV-1 vectors is their instability of transgene expression. By contrast, vectors based on adeno-associated virus (AAV) can either persist in an episomal form or integrate into the host cell genome, thereby supporting long-term gene expression. AAV expresses four rep genes, rep68, -78, -40, and -52. Of those, rep68 or rep78 are sufficient to mediate site-specific integration of the AAV DNA into the host cell genome. The major disadvantage of AAV vectors is the small transgene capacity ( approximately 4.6 kb). In this study, we constructed HSV/AAV hybrid vectors that contained, in addition to the standard HSV-1 amplicon elements, AAV rep68, rep78, both rep68 and -78, or all four rep genes and a reporter gene that was flanked by the AAV inverted terminal repeats (ITRs). Southern blots of Hirt DNA from cells transfected with the hybrid vectors and HSV-1 helper DNA demonstrated that both the AAV elements and the HSV-1 elements were functional in the context of the hybrid vector. All hybrid vectors could be packaged into HSV-1 virions, although those containing rep sequences had lower titers than vectors that did not. Site-specific integration at AAVS1 on human chromosome 19 was directly demonstrated by PCR and sequence analysis of ITR-AAVS1 junctions in hybrid vector-transduced 293 cells. Cell clones that stably expressed the transgene for at least 12 months could easily be isolated without chemical selection. In the majority of these clones, the transgene cassette was integrated at AAVS1, and no sequences outside the ITR cassette, rep in particular, were present as determined by PCR, ITR rescue/replication assays, and Southern analysis. Some of the clones contained random integrations of the transgene cassette alone or together with sequences outside the ITR cassette. These data indicate that the long-term transgene expression observed following transduction with HSV/AAV hybrid vectors is, at least in part, supported by chromosomal integration of the transgene cassette, both randomly and site specifically.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12072516      PMCID: PMC136299          DOI: 10.1128/jvi.76.14.7163-7173.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Gene transfer to the nigrostriatal system by hybrid herpes simplex virus/adeno-associated virus amplicon vectors.

Authors:  L C Costantini; D R Jacoby; S Wang; C Fraefel; X O Breakefield; O Isacson
Journal:  Hum Gene Ther       Date:  1999-10-10       Impact factor: 5.695

2.  Selective extraction of polyoma DNA from infected mouse cell cultures.

Authors:  B Hirt
Journal:  J Mol Biol       Date:  1967-06-14       Impact factor: 5.469

3.  An infectious transfer and expression system for genomic DNA loci in human and mouse cells.

Authors:  R Wade-Martins; E R Smith; E Tyminski; E A Chiocca; Y Saeki
Journal:  Nat Biotechnol       Date:  2001-11       Impact factor: 54.908

4.  HSV-1 amplicon vectors are a highly efficient gene delivery system for skeletal muscle myoblasts and myotubes.

Authors:  Y Wang; C Fraefel; F Protasi; R A Moore; J D Fessenden; I N Pessah; A DiFrancesco; X Breakefield; P D Allen
Journal:  Am J Physiol Cell Physiol       Date:  2000-03       Impact factor: 4.249

5.  Transposon vectors containing non-antibiotic resistance selection markers for cloning and stable chromosomal insertion of foreign genes in gram-negative bacteria.

Authors:  M Herrero; V de Lorenzo; K N Timmis
Journal:  J Bacteriol       Date:  1990-11       Impact factor: 3.490

6.  Detection of adeno-associated virus (AAV)-specific nucleotide sequences in DNA isolated from latently infected Detroit 6 cells.

Authors:  K I Berns; T C Pinkerton; G F Thomas; M D Hoggan
Journal:  Virology       Date:  1975-12       Impact factor: 3.616

7.  Site-specific integration by adeno-associated virus.

Authors:  R M Kotin; M Siniscalco; R J Samulski; X D Zhu; L Hunter; C A Laughlin; S McLaughlin; N Muzyczka; M Rocchi; K I Berns
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

8.  A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons.

Authors:  A I Geller; X O Breakefield
Journal:  Science       Date:  1988-09-23       Impact factor: 47.728

9.  Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice.

Authors:  R A Willis; W J Bowers; M J Turner; T L Fisher; C S Abdul-Alim; D F Howard; H J Federoff; E M Lord; J G Frelinger
Journal:  Hum Gene Ther       Date:  2001-10-10       Impact factor: 5.695

10.  Herpes simplex virus type 1/adeno-associated virus rep(+) hybrid amplicon vector improves the stability of transgene expression in human cells by site-specific integration.

Authors:  Y Wang; S M Camp; M Niwano; X Shen; J C Bakowska; X O Breakefield; P D Allen
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

View more
  16 in total

1.  Efficient site-specific integration of large transgenes by an enhanced herpes simplex virus/adeno-associated virus hybrid amplicon vector.

Authors:  Qiang Liu; Claudio F Perez; Yaming Wang
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

2.  Differential contribution of adeno-associated virus type 2 Rep protein expression and nucleic acid elements to inhibition of adenoviral replication in cis and in trans.

Authors:  Stefan Weger; Eva Hammer; Regine Heilbronn
Journal:  J Virol       Date:  2014-10-01       Impact factor: 5.103

3.  A helper-dependent capsid-modified adenovirus vector expressing adeno-associated virus rep78 mediates site-specific integration of a 27-kilobase transgene cassette.

Authors:  Hongjie Wang; André Lieber
Journal:  J Virol       Date:  2006-09-20       Impact factor: 5.103

4.  Four-dimensional visualization of the simultaneous activity of alternative adeno-associated virus replication origins.

Authors:  Daniel L Glauser; Okay Saydam; N Alexander Balsiger; Irma Heid; R Michael Linden; Mathias Ackermann; Cornel Fraefel
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

5.  Plasmid DNA sequences present in conventional herpes simplex virus amplicon vectors cause rapid transgene silencing by forming inactive chromatin.

Authors:  Masataka Suzuki; Kazue Kasai; Yoshinaga Saeki
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

6.  Herpes simplex virus type 1/adeno-associated virus hybrid vectors.

Authors:  Anna Paula de Oliveira; Cornel Fraefel
Journal:  Open Virol J       Date:  2010-06-18

7.  Spatial and temporal organization of adeno-associated virus DNA replication in live cells.

Authors:  Cornel Fraefel; Anne Greet Bittermann; Hansruedi Büeler; Irma Heid; Thomas Bächi; Mathias Ackermann
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

8.  Herpes simplex virus type 1/adeno-associated virus rep(+) hybrid amplicon vector improves the stability of transgene expression in human cells by site-specific integration.

Authors:  Y Wang; S M Camp; M Niwano; X Shen; J C Bakowska; X O Breakefield; P D Allen
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

9.  Extending the transposable payload limit of Sleeping Beauty (SB) using the Herpes Simplex Virus (HSV)/SB amplicon-vector platform.

Authors:  S de Silva; M A Mastrangelo; L T Lotta; C A Burris; H J Federoff; W J Bowers
Journal:  Gene Ther       Date:  2009-10-29       Impact factor: 5.250

10.  ICP0 inhibits the decrease of HSV amplicon-mediated transgene expression.

Authors:  Masataka Suzuki; Kazue Kasai; Akihiro Ohtsuki; Jakub Godlewski; Michal O Nowicki; E Antonio Chiocca; Yoshinaga Saeki
Journal:  Mol Ther       Date:  2009-02-17       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.